Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00655)
Name
Telbivudine
Synonyms    Click to Show/Hide the Synonyms of This API
Telbivudine; Epavudine; 2'-Deoxy-L-thymidine; L-Thymidine; beta-L-Thymidine; 3424-98-4; Telbivudin; Tyzeka; L-Deoxythymidine; Sebivo; NV-02B; LDT600; beta-L-2'-Deoxythymidine; NV 02B; UNII-2OC4HKD3SF; CHEBI:63624; LDT-600; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2OC4HKD3SF; 26879-47-0; 1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-deoxy-beta-L-ribofuranosyl)-5-methyluracil; MFCD02683612; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; Tyzeka (TN); Telbivudine (USAN/INN); Telbivudine [USAN:INN:BAN]; 5-methyl-l-uridine; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; b-L-2'-deoxy-thymidine; SCHEMBL124279; Telbivudine (Sebivo, Tyzeka); CHEMBL374731; Epavudine;L-Thymidine;NV 02B; Thymine, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-; ZINC2159; Telbivudine, >=98% (HPLC); DTXSID30187813; HY-B0017; BDBM50088372; AKOS025117349; AC-5632; CCG-266887; CS-1934; DB01265; SB20806; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-Pyrimidinedione; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-b-L-erythro-pentofuranosyl)-5-methyl-; NCGC00346560-01; NCGC00346560-06; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; AS-35209; SW220236-1; D06675; AB01274717-01; AB01274717_02; Q413621; BRD-K15976406-001-01-7; Thymine, 1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-; Z2574360267; 1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-((2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; L-thymidine; beta-L-thymidine; L-dT; 2'-deoxy-L-thymidine; 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione
Clinical Status
Approved
Disease Indication Viral hepatitis ICD-11: 1E51 [1]
PubChem CID
159269
Formula
C10H14N2O5
Canonical SMILES
CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O
InChI
1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1
InChIKey
IQFYYKKMVGJFEH-CSMHCCOUSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=159269"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 242.23 Topological Polar Surface Area 99.1
XlogP -1.2 Complexity 381
Heavy Atom Count 17 Rotatable Bond Count 2
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
Full List of Drug Formulations (DFMs) Containing This API
          Telbivudine 600 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Talc; Titanium dioxide; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols; Povidones; Sodium starch glycolate type a potato
                   Dosage Form Oral Tablet
                   Company Novartis Pharmaceuticals Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
References
1 FDA label for approved telbivudine from the official website of the U.S. Food and Drug Administration.
2 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.